Allogene Therapeutics (ALLO) EBITDA Yield: History & Chart

Allogene Therapeutics, Inc.(ALLO)

Biotechnology · South San Francisco, CA

$1.44-0.06 (-4.00%)

Delayed quote: Oct 6, 2026, 10:20 AM EDT

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

151 employees

www.allogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zachary Roberts

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Allogene Therapeutics, Inc. (ALLO)	$498.75M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$507.55M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$513.25M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$516.46M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$521.76M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$473.57M	N/A	N/A	N/A	N/A
Bright Minds Biosciences Inc. (DRUG)vs ›	$473.36M	N/A	N/A	N/A	N/A
Arvinas, Inc. (ARVN)vs ›	$471.65M	N/A	N/A	N/A	N/A
Contineum Therapeutics, Inc. (CTNM)vs ›	$471.20M	N/A	25.96%	19.61%	19.61%
Crescent Biopharma, Inc. (CBIO)vs ›	$531.34M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Allogene Therapeutics, Inc. (ALLO)

$498.75M

N/A

Monopar Therapeutics Inc. (MNPR)vs ›

$507.55M

N/A

908 Devices Inc. (MASS)vs ›

$513.25M

N/A

Altimmune, Inc. (ALT)vs ›

$516.46M

N/A

Immix Biopharma, Inc. (IMMX)vs ›

$521.76M

N/A

Evolus, Inc. (EOLS)vs ›

$473.57M

N/A

Bright Minds Biosciences Inc. (DRUG)vs ›

$473.36M

N/A

Arvinas, Inc. (ARVN)vs ›

$471.65M

N/A

Contineum Therapeutics, Inc. (CTNM)vs ›

$471.20M

N/A

25.96%

19.61%

Crescent Biopharma, Inc. (CBIO)vs ›

$531.34M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

ALLO EBITDA Yield Metrics

ALLO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics